348 related articles for article (PubMed ID: 29682899)
1. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
6. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
[TBL] [Abstract][Full Text] [Related]
7. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
9. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
[TBL] [Abstract][Full Text] [Related]
11. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
[TBL] [Abstract][Full Text] [Related]
13. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.
Youn B; Trikalinos NA; Mor V; Wilson IB; Dahabreh IJ
Cancer; 2020 Mar; 126(5):978-985. PubMed ID: 31943163
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
15. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract][Full Text] [Related]
16. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
17. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
Kataoka Y; Hirano K; Narabayashi T; Hara S; Fujimoto D; Tanaka T; Ebi N; Tomii K; Yoshioka H
Cancer Chemother Pharmacol; 2018 Feb; 81(2):333-337. PubMed ID: 29230503
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
19. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
20. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
